EyeBio’s main asset is Restoret, an intravitreally delivered trispecific antibody that acts as an agonist of the Wnt signalling pathway and is in the phase 1b/2a AMARONE study in DME and ...

“There are two advanced forms of AMD: the wet form or neovascular form, [for which] there are treatments, there are medicines we inject intravitreally in patients routinely, and we’ve been ...

Welcome to the latest issue of Blockbuster Biologics Review, which covers the status and developments of post-grant challenges and patent litigations implicating blockbuster biologics and ...

Expert Rev Ophthalmol. 2013;8(3):227-235. The use of anti-VEGF is rapidly becoming the standard of care for retinal vascular disease. There remains some concern regarding the duration of treatment ...

It has been administered to over 140 patients across various cancers in clinical trials. For retinoblastoma, the therapy has been given intravitreally, directly into the eye. Steven A. Shallcross, CEO ...